Related Experiment Video
Updated: May 5, 2026
08:04
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
12.8K
Progress in histology specific treatments in soft tissue sarcoma
Stefano Radaelli1, Alessandra Merlini2,3, Misbah Khan4
1Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Expert Review of Anticancer Therapy
|August 5, 2024
Summary
Soft tissue sarcomas (STS) treatments are advancing with chemotherapy and radiotherapy. Further research is needed to understand targeted therapy and immunotherapy effectiveness for STS patients.
Area of Science:
- Oncology
- Surgical Oncology
- Medical Oncology
Background:
- Soft tissue sarcomas (STS) are rare, heterogeneous tumors primarily managed with surgery.
- High-risk extremity STS often benefits from preoperative radiotherapy.
- Neoadjuvant chemotherapy, including doxorubicin and ifosfamide, shows efficacy in specific STS locations.
Purpose of the Study:
- To review the current treatment landscape for localized and metastatic soft tissue sarcomas.
- To emphasize innovative, histopathology-driven therapeutic approaches.
- To incorporate information on ongoing clinical trials for STS.
Main Methods:
- Extensive PubMed literature search.
- Inclusion of data from clinicaltrials.gov.
- Focus on combined radiotherapy and chemotherapy strategies.
Main Results:
- Recent advancements in STS treatment are emerging from clinical trial outcomes.
- Chemotherapy, targeted therapy, and immunotherapy are key areas of investigation.
- Histopathology-driven approaches are becoming increasingly important.
Conclusions:
- Further research is essential to elucidate the roles of chemotherapy, targeted therapy, and immunotherapy in STS.
- Identifying predictive biomarkers is crucial for personalized STS treatment.
- Clinical trials are driving progress in understanding and treating soft tissue sarcomas.
